Network architecture for lithography machine cluster

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Mapper Lithography Ip B.V. patent solves the following problem:

The invention relates to a clustered substrate processing system comprising a plurality of elements lithography each arranged independent exposure of substrates according to data standards, and especially in network architecture for such a clustered substrate processing system.

Our analysis of this patent is as follows:

Mapper Lithography Ip B.V.’s patent US 9244726 B2 deals with Network architecture for lithography machine cluster.
The invention relates to a clustered substrate processing system comprising a plurality of elements lithography. Each lithography elements arranged for independent exposure of substrates according to data standards, and contains a number of lithography subsystems, a control network arranged for communication control information between the lithography subsystems and at least one element in the control unit, the control unit elements arranged to transmit commands lithography subsystems and lithography subsystems arranged passage in response to the element control unit, and a data network arranged for communication data logging information from the lithography subsystems at least some of the data network hub, the lithography subsystems arranged for transmitting data logging information into the data network hub and the data hub arranged for receiving and storing the data the logging information. The system further comprises a cluster of front-end interface for an operator or host system.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Pfenex, Inc. patent solves the following problem:

The use of bacterial cells to produce protein-based therapeutics is increasing in commercial importance. One of the goals of developing a bacterial expression system is the production of high quality polypeptides target quickly, efficiently, and in abundance. An ideal host cell for such an expression system that can efficiently use a carbon source for the production of a target polypeptide, quickly grow to high cell densities in a fermentation reaction , expression of the target polypeptide only when induced, and grow in a medium that is the regulatory and environmental concerns.

Our analysis of this patent is as follows:

Pfenex, Inc.’s patent US 9243253 B2 deals with Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein.
If there are methods and compositions for the expression of a nucleic acid make up nucleic acid encoding a) a synthetic polypeptide, and b) a prototrophy-restoring enzyme in a host cell auxotrophic for at least one metabolite. In various embodiments, the host cells auxotrophic for a nitrogenous base compound or an amino acid. invention includes identifying an analogue of the growth media for the host cell so that the analogue incorporated into the artificial polypeptide or a nucleic acid coding it. In various embodiments, the compositions and methods disclosed here resulting in better artificial protein expression compared to the expression of recombinant proteins in an antibiotic selection system, or compared the expression of recombinant proteins in a expression system without a metabolite analogue.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Detection and treatment of LRP4-associated neurotransmission disorders

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Georgia Regents Research Institute, Inc. patent solves the following problem:

Myasthenia gravis is an autoimmune disease that causes dysfunction of nerves and muscle synapses. Seventy percent of patients with myasthenia gravis carry autoantibodies to acetylcholine receptor (ACHR) and a special 10% carrying muscle autoantibodies specific tyrosine kinase (musk) (Vincent and Leite, 2005, Curr Opin Neurol; 18 (5) : 519-25). However, twenty percent of patients with myasthenia gravis seronegative for autoantibodies ACHR and musk. Therefore, there is a need for improved diagnostic and treatment methods for nerve and muscle disorder such as myasthenia gravis.

Our analysis of this patent is as follows:

Georgia Regents Research Institute, Inc.’s patent US 9244082 B2 deals with Detection and treatment of LRP4-associated neurotransmission disorders.
The present invention includes methods for the detection of neurotransmission or developmental disorder, including, but not limited to, myasthenia gravis seronegative for autoantibodies to acetylcholine receptor (ACHR) and / or muscle specific tyrosine kinase (musk), the method including detecting autoantibodies that bind LRP4, or an epitope thereof. also includes methods for the treatment of an individual suffering from a neurotransmission disorder, the method including the detection of a fluid physical respective autoantibodies that bind LRP4, or an epitope and administering to the patient an effective amount of an immunosuppressant and / or other suitable therapeutic modality. As well as antibodies that bind to these autoantibodies LRP4 and kits for the detection of neurotransmission or developmental disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and compositions related to immunogenic fibrils

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The University Of Chicago patent solves the following problem:

I. Field of Invention

Our analysis of this patent is as follows:

The University Of Chicago’s patent US 9241987 B2 deals with Methods and compositions related to immunogenic fibrils.
Embodiments of the invention is directed to the fibrillar adjuvants. Epitopes assembled into nanofibers through a short artificial fibrillization domain elicited high antibody titers in the absence of any adjuvant.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Corning Incorporated patent solves the following problem:

The design of a packaged pharmaceutical composition in general seeks to provide an active pharmaceutical ingredient (API) in an appropriate package easy to use, which maintains the strength of API prolonged storage , and that allows for the delivery of effective, strong, active, nontoxic and nondegraded API.

Our analysis of this patent is as follows:

Corning Incorporated’s patent US 9241869 B2 deals with Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients.
The present invention is based, at least in part, upon the recognition of a pharmaceutical container formed, at least in part, to a glass composition that shows a reduced propensity to delaminate, ie , a reduced tendency to shed glass particulates. As a result, the presently claimed vessel most suited for the storage of pharmaceutical compositions and, especially, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LEVEMIR NOVOLOG, NOVOLIN 70-30, NOVOLIN R, NOVOLIN A, NOVOLOG Mix 70 -30 and NOVOLIN L.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions and methods for detecting vitamin D

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Siemens Healthcare Diagnostics Inc. patent solves the following problem:

This invention relates to compositions, methods and kits for determining the presence and / or amount of vitamin D and vitamin D analogs and its metabolites in a sample suspected of containing the same.

Our analysis of this patent is as follows:

Siemens Healthcare Diagnostics Inc.’s patent US 9244083 B2 deals with Compositions and methods for detecting vitamin D.
Compounds include carbamate derivatives of vitamin D and vitamin D3and vitamin D2. The compounds are useful in methods and kits for determining the presence and / or amount of vitamin D and vitamin D analogs and its metabolites in a sample suspected of containing the same.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for detecting vitamin D metabolites by mass spectrometry

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Quest Diagnostics Investments Incorporated patent solves the following problem:

Vitamin D is an essential nutrient with important physiological role in the positive regulation of calcium (Ca2 +) homeostasis. Vitamin D may be de novo in the skin by exposure to sunlight or it may be absorbed from food. There are two forms of vitamin D; Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D3 is the form synthesized de novo in animals. It is also a common supplement in addition to dairy products and some food products made in the United States. Both dietary and natural synthesized vitamin D3 should undergo metabolic activation to produce bioactive metabolites. In men, the initial steps of vitamin D3 activation occurs primarily in the liver and include hydroxylation to form intermediate metabolite 25-hydroxyvitamin D3 (25-hydroxycholecalciferol; calcifediol; 25OHD3). Calcifediol is the major form of vitamin D3 in circulation. Rotating 25OHD3 then converted by the kidney to 1,25-dihydroxyvitamin D3 (calcitriol; 1,25 (OH) 2d3), commonly believed that the metabolite of vitamin D3 with the highest biological activity.

Our analysis of this patent is as follows:

Quest Diagnostics Investments Incorporated’s patent US 9244084 B2 deals with Methods for detecting vitamin D metabolites by mass spectrometry.
If the methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and identify the amount of ion to determine the presence or amount of vitamin D metabolite in the sample. Also provides methods to identify the presence or amount of two or more of vitamin D metabolites in one assay.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for killing PSMA-expressing, taxane-resistant cancer cells

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Psma Development Company, Llc patent solves the following problem:

Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States (Jemal A, et al, CA Cancer J Clin 2005; 55 :. Proceeds from 10-30). Localized prostate cancer is usually treated with surgery or radiation, and chronic diseases can be controlled temporarily with androgen ablation (Klein EA, et al, Urol Clin North Am 2003; 30 :. 315-30). However, almost all of the prostate carcinoma eventually becomes hormone rebelled and rapid growth (Denmeade SR, et al, Nat Rev Cancer 2002; 2 .: 389-96). Hormone-rebellious or androgen-independent prostate cancer proved to be most resistant to conventional chemotherapy. With the exception of palliative care, the only approved chemotherapy is docetaxel in combination with prednisone, which offers a modest (2.4 months) survival benefit (Gulley J, et al, Am J Father 2004; 351 :. . 1513-20; Petrylak DP, et al, New Engl J Med 2004; 351 :. 1513-20).

Our analysis of this patent is as follows:

Psma Development Company, Llc’s patent US 9242012 B2 deals with Methods for killing PSMA-expressing, taxane-resistant cancer cells.
Methods of killing prostate-specific membrane antigen (PSMA) -expressing, Taxane-resistant cancer cells given. In particular, PSMA-expressing, Taxane-resistant cancer cells contacted with an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated monomethylauristatin norephedrine or monomethylauristatin phenylalanine.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Targeted pyrrolobenzodiazapine conjugates

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Seattle Genetics Inc., , Medimmune Limited patent solves the following problem:

Some pyrrolobenzodiazepines (PBDS) the ability to recognize and bond to specific sequences of DNA; The preferred is PuGPu. The first PBD antitumour antibiotic, anthramycin, discovered in 1965 (Leimgruber, et al, J. Am Chem Soc, 87, 5793-5795 (1965); ……. Leimgruber, et al, J. Am Chem Soc. 87, 5791-5793 (1965)). Since then, a number of naturally occurring PBDS report, and over 10 synthetic routes has developed a variety of analogues (Thurston, et al., Chem. Rev. 1994, 433-465 (1994 )). family members include abbeymycin (Hochlowski, et al., J. Antibiotics, 40, 145-148 (1987)), chicamycin (Konishi, et al., J. Antibiotics, 37, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al, Chem British, 26, 767-772 (1990) ;. Bose, et al, Tetrahedron, 48, 751-758 (1992)), mazethramycin (Kuminoto, et al., J. Antibiotics, 33, 665-667 (1980)), neothramycins A and B (Takeuchi, et al., J. Antibiotics, 29, 93-96 (1976)), porothramycin (Tsunakawa , et al., J. Antibiotics, 41, 1366-1373 (1988)), prothracarcin (Shimizu, et al, J. Antibiotics, 29, 2492-2503 (1982); Langley and Thurston, J. org Chem, 52, 91- 97 (1987)), sibanomicin (DC-102) (Hara, et al, J. Antibiotics, 41, 702-704 (1988) .. Itoh, et al, J. Antibiotics, 41, 1281- 1284 (1988)), sibiromycin (Leber, et al., J. Am. Chem. Soc., 110, 2992-2993 (1988)) and tomamycin (Arima, et al., J. Antibiotics, 25, 437-444 (1972)). PBDS is the general structure:

Our analysis of this patent is as follows:

Seattle Genetics Inc., , Medimmune Limited’s patent US 9242013 B2 deals with Targeted pyrrolobenzodiazapine conjugates.
If Conjugate constitute PBDS conjugated to a targeting agent and methods of using such PBDS.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Regents Of The University Of California patent solves the following problem:

The present invention relates generally to a chain Fv fragments of the tumor-associated antigen binding antibody. invention further relates to a chain Fv conjugate molecules and their use in the delivery of biologically active molecules in cancer cells as well as the management of T cells in response to tumor-associated antigen expressing cells cancer.

Our analysis of this patent is as follows:

The Regents Of The University Of California’s patent US 9242014 B2 deals with Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof.
Composition including an antibody single-chain variable fragments (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen given. The anti-ROR1 scFv antibody conjugates may include a biologically active molecule. Such conjugates may contain a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods of using scFv conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.